TESTING UPDATE
GIAnomics™ OncoPredikt HRD Assay

SUMMARY:

- OncoPredikt HRD Assay is designed to identify genomic signatures associated with Homologous Recombination Deficiency in cancer patients
- Ideal for HRD Screening Pharma Development
- AI Enabled Algorithm
- Cost effective

CLINICAL UTILITY:

- Quickly and easily identify HRD status in cancer patients
- Identify patients that are likely candidates for PARPi therapy
- Assay Performance Characteristics [1]:

  Accuracy = 99.3%; Sensitivity = 100%; Specificity = 99%

METHOD: AI Enabled Imaging

TURN AROUND TIME: 3-4 days

SPECIMEN: H&E Stained Slide; Formalin fixed paraffin embedded (FFPE) tissue

STORAGE/TRANSPORTATION: Room temperature

Note: OncoPredikt HRD was evaluated, and its performance characteristics determined, by Genetics Institute of America. It has not been cleared or approved by the U.S Food and Drug Administration. Such clearance or approval is generally not necessary. Genetics Institute of America is certified under the Clinical Laboratory Improvement Act of 1988 (CLIA) as qualified to perform high complexity testing. This test is currently offered as Research Use Only (RUO).

For Supplies, To Order or for More Information
Please contact your local GIA Representative or Contact Business Development at:
833-443-6522 ext 702 or ProviderServices@GenLabUS.com

1 AI-enabled identification prediction of homologous recombination deficiency (HRD) from histopathology images. Gowhar Shafi, Shivamurthy P.M., Anand Ulle, Krithika Srinivasan, Aravindan Vasudevan, Vikas Jadhav, Dr Sujit Joshi, Nirmal Vivek Raut, Jayant Khandare, Mohan Uttarwar, and Kenneth Joel Bloom. Journal of Clinical Oncology 2022 40:16_suppl, 3019-3019